Voyager Therapeutics ( VYGR ) Reports Q2 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -18.75% and -55.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant ...
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - Voyager Therapeutics ( NASDAQ:VYGR )
LEXINGTON, Mass., June 10, 2025 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. VYGR, a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W.
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
LEXINGTON, Mass., June 10, 2025 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. ( Nasdaq: VYGR ) , a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional ...
Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders
- $60 million Series A led by Atlas Venture, and founded by an expert team of physicians and scientists - VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for fourth quarter of 2025
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication - Voyager Therapeutics ( NASDAQ:VYGR )
LEXINGTON, Mass., May 15, 2025 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. VYGR, a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase ( ALPL ) to ...
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
LEXINGTON, Mass., May 15, 2025 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. ( Nasdaq: VYGR ) , a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline ...
Voyager Therapeutics ( VYGR ) Reports Q1 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -51.43% and 66.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting - Voyager Therapeutics ( NASDAQ:VYGR )
- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg -
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of ...
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025 - Voyager Therapeutics ( NASDAQ:VYGR )
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the ...
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study ...
Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm - Dave ( NASDAQ:DAVE ) , Perpetua Resources ( NASDAQ:PPTA )
NEW YORK, March 20, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Dave, Inc. DAVE, Red Cat Holdings, Inc. RCAT, Perpetua Resources Corp. PPTA, and Voyager Therapeutics, Inc.
Voyager Therapeutics ( VYGR ) Reports Q4 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -68.57% and 68.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics ( CTMX ) Tops Q4 Earnings and Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 210% and 89.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. ( TCRX ) Reports Q4 Loss, Lags Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of -7.41% and 53.59%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
LEXINGTON, Mass., March 04, 2025 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. ( Nasdaq: VYGR ) , a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, ...
Voyager Reports Positive Topline Data for Single Ascending Dose ( SAD ) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose ( MAD ) Trial in Alzheimer's Disease
- Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile ...
Day One Biopharmaceuticals, Inc. ( DAWN ) Reports Q4 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of -97.14% and 7.74%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. ( VYGR ) on Behalf of Investors - Voyager Therapeutics ( NASDAQ:VYGR )
NEW YORK, Feb. 19, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Kirby McInerney LLP is investigating potential claims against Voyager Therapeutics, Inc. ( "Voyager" or the "Company" ) VYGR. The investigation concerns whether Voyager and/or certain of its officers have violated the federal ...
What Makes Voyager Therapeutics ( VYGR ) a New Buy Stock
Voyager Therapeutics (VYGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MRK Reports Mixed Keytruda Combo Study Data in Gastroesophageal Cancer
The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal adenocarcinoma.
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?
Here, we discuss some reasons why investing in BEAM stock now may turn out to be a prudent move.
Axsome Shares Rise 19% in a Month: What's Driving the Rally?
AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while Sunosi diversifies its business.
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate
Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on July 22, 2025.
J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use
The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer
The FDA approves Amgen's Lumakras in combination with Vectibix for treating previously treated adults with KRAS G12C-mutated metastatic colorectal cancer.
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
Here, we discuss some reasons why investing in STOK now may turn out to be a prudent move.
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results
Mirum stock rallies this week on upbeat preliminary 2024 results, the 2025 outlook and anticipated pipeline goals.
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals ( Revised )
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise
TG Therapeutics reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides revenue guidance for 2025 and other pipeline goals.
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down
SpringWorks reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides updates across the commercial portfolio and other pipelines.
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025.
Wall Street Analysts See a 152.53% Upside in Voyager Therapeutics ( VYGR ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 152.5% in Voyager Therapeutics (VYGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer's Disease - Voyager Therapeutics ( NASDAQ:VYGR )
- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro gene therapy development candidate nominated leveraging Voyager's IV-delivered, CNS-penetrant TRACER capsids -
Voyager Therapeutics ( VYGR ) Reports Q3 Loss, Tops Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 64.44% and 95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences, Inc. ( RCUS ) Reports Q3 Loss, Tops Revenue Estimates
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 6.54% and 43.97%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - Voyager Therapeutics ( NASDAQ:VYGR )
LEXINGTON, Mass., Nov. 06, 2024 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. VYGR, a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences:
Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
LEXINGTON, Mass., Nov. 05, 2024 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. ( Nasdaq: VYGR ) , a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November 12, ...
Rhythm Pharmaceuticals, Inc. ( RYTM ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Voyager Therapeutics ( VYGR ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Voyager Therapeutics (VYGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sage Therapeutics to Reduce Workforce by 33%, Stock Down
SAGE announces a portfolio reprioritization plan to focus on the launch of the depression drug Zurzuvae and other pipeline developments. Stock falls in after-hours trading.
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review
The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.
SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies
Sanofi inks an agreement with Orano Med to develop next-generation radioligand medicines to treat rare cancers.
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
The FDA bestows an orphan drug designation to Immuneering's lead candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares rise.
Bicycle Therapeutics ( BCYC ) Soars 5.7%: Is Further Upside Left in the Stock?
Bicycle Therapeutics (BCYC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Voyager Therapeutics ( VYGR ) : Can Its 17.5% Jump Turn into More Strength?
Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
